Unity Biotechnology, Inc. financial data

Symbol
UBX on Nasdaq
Industry
Pharmaceutical Preparations
Location
285 East Grand Avenue, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Cenexys, Inc. (to 7/15/2013), Forge Inc (to 5/5/2009)
Latest financial report
10-K - Q4 2024 - Mar 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 373 % -11.8%
Debt-to-equity 206 % +55%
Return On Equity -161 % -52.2%
Return On Assets -52.7 % -15.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.9M shares +0.48%
Common Stock, Shares, Outstanding 16.9M shares +0.48%
Entity Public Float 22.5M USD -34%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 16.8M shares +13.9%
Weighted Average Number of Shares Outstanding, Diluted 16.8M shares +13.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 13M USD -35.3%
General and Administrative Expense 15.5M USD -18.5%
Operating Income (Loss) -31.2M USD +30.2%
Net Income (Loss) Attributable to Parent -26M USD +34.8%
Earnings Per Share, Basic -1.54 USD/shares +43%
Earnings Per Share, Diluted -1.54 USD/shares +43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.58M USD -61.7%
Marketable Securities, Current 15.7M USD -33.1%
Assets, Current 24.3M USD -47.9%
Property, Plant and Equipment, Net 3.46M USD -32%
Operating Lease, Right-of-Use Asset 8.9M USD -31.4%
Other Assets, Noncurrent 143K USD +13.5%
Assets 37.7M USD -42.7%
Accounts Payable, Current 997K USD -27.8%
Accrued Liabilities, Current 6.17M USD +33.5%
Liabilities, Current 9.26M USD +18.1%
Operating Lease, Liability, Noncurrent 19.7M USD -16.3%
Liabilities 31.2M USD -16.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 15K USD
Retained Earnings (Accumulated Deficit) -510M USD -5.37%
Stockholders' Equity Attributable to Parent 6.49M USD -77.1%
Liabilities and Equity 37.7M USD -42.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.18M USD +54.2%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -7.19M USD -134%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 16.9M shares +0.48%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.4M USD -221%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.48M USD -59.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 118M USD +7.42%
Deferred Tax Assets, Gross 121M USD +5.99%
Operating Lease, Liability 23.5M USD -12.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -26M USD +34.5%
Lessee, Operating Lease, Liability, to be Paid 27.3M USD -15.4%
Property, Plant and Equipment, Gross 12.7M USD -11.5%
Operating Lease, Liability, Current 3.83M USD +11%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.29M USD +3.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.12M USD +3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.76M USD -28.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.46M USD +3.22%
Deferred Tax Assets, Operating Loss Carryforwards 88.8M USD +9.55%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 17.5M USD +0.19%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.63M USD +3.23%
Operating Lease, Payments 1.2M USD -29.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 227K USD -31%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.97M USD -46.5%
Interest Expense 1.45M USD -61.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%